Current Perspective

Are rapidly growing cancers more lethal?

Hans-Olov Adami a,b,c,#, Peter Csermely d, Daniel V. Veres d,e, Louise Emilsson a,c,f, Magnus Løberg a,g, Michael Bretthauer a,g,1, Mette Kalager a,g,1

a Clinical Effectiveness Research Group, Institute of Health and Society, University of Oslo, Oslo, Norway
b Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
c Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA
d Department of Medical Chemistry, Semmelweis University, Budapest, Hungary
e Turbine Ltd., Budapest, Hungary
f Primary Care Research Unit, Vårdfcentralen Värmlands Nysäter, Värmland County, Sweden
g Oslo University Hospital, Department of Transplantation Medicine and K. G. Jebsen Center for Colorectal Cancer Research, Oslo, Norway

Received 4 November 2016; accepted 11 November 2016

Abstract The view, that rapidly growing tumours are more likely than slow-growing tumours to metastasize and become lethal, has remained almost axiomatic for decades. Unaware of any solid evidence supporting this view, we undertook an exhaustive system-level analysis of intra- and intercellular signalling networks. This analysis indicated that rapid growth and metastasis are often different outcomes of complex integrated molecular events. Evidence from humans can be derived chiefly from screening interventions because interval cancers that surface clinically shortly after a negative screening test are, on average, more rapidly growing than cancers not detected by screening. We reviewed all available data limited to cancers of the breast, cervix and large bowel. The evidence from humans provides no support for the theory that rapidly growing cancers are more prone to metastasize. These findings indicate that the prevailing view should be reconsidered, as should the impact of length-biased sampling in cancer screening, and the findings provide no support for treating interval cancers more aggressively than non-interval cancers.

© 2016 Elsevier Ltd. All rights reserved.

# Corresponding author: Department of Epidemiology, Harvard T.H. Chan School of Public Health, Huntington Avenue 677, Boston, MA 02115, USA.
E-mail address: hadami@hsph.harvard.edu (H.-O. Adami).
1 These authors contributed equally.

http://dx.doi.org/10.1016/j.ejca.2016.11.011
0959-8049 © 2016 Elsevier Ltd. All rights reserved.
1. Introduction

Cancer screening has been described as a clash between science and intuition [1]. The same might hold for the almost axiomatic long-held view that rapidly growing tumours are more likely to metastasize and become lethal than slow-growing tumours [2–4]. This view seems to be integrated into daily thinking among doctors treating cancer patients but is also conveyed in the scholarly literature (e.g.: [5–7]). Evidence to support or refute this theory may come from molecular biology, because cancer is a system-level disease, and somatic mutations and signalling pathways that entail accelerated tumour growth would also promote dissemination of malignant cells that create distant metastases. But the ultimate proof must come from human studies investigating the prognosis of individuals with cancer. There is now compelling evidence to indicate that cancer growth rate and metastases are not related phenomena. This challenges the assessment of screening interventions [2–4] and possibly also the management of cancer patients.

2. Evidence from tumour biology

Already in 1958, in an exhaustive review of the natural history of cancer, Foulds discussed growth rate and metastatic potential as separate, distinct features of a malignant tumour [8]. Foulds emphasised that ‘growth rate, local invasion, spread to regional lymph nodes, and dissemination to the blood stream are independently variable characteristics’. He concluded that ‘a survey of varied types of neoplasia reveals patterns of development common to all of them’, suggesting that the evidence from one or a few cancer sites might be generalisable to others. The explosive expansion of knowledge from molecular biology may now allow a deeper understanding of the signalling complexity that governs growth rate and the metastatic process.

Tumour growth and metastasis were defined as separate hallmarks of cancer, implying that their molecular background is different. However, somatic mutations occurring in related genes often have overlapping functions [9]. In addition, cross-talk between various signalling pathways makes it difficult to clearly distinguish between ‘tumour growth pathways’ and ‘metastasis pathways’. Nevertheless, an increasing amount of recent scientific evidence demonstrates that the development of the rapid growth versus metastatic phenotypes can be distinguished as separate, context-dependent outcomes of the whole signalling network [10–12].

Cancer stem-like cells and cancer cell dormancy are special examples of this context-dependent duality. Cancer stem-like cells may reside in one of the two basic states in their signalling network: namely, either in a rapidly proliferating state or in a quiescent, metastasis-inducing state [13]. Rapid proliferation or metastasis-prone phenotypes of both states develop as a result of a finely tuned balance between signalling pathways.

Primary tumours have an extremely great cellular heterogeneity [14,15]. In addition to the various mutational DNA rearrangement, DNA copy number, gene expression, proteome, phosphoproteome and other ‘omic’ differences of individual cancer cells, they display different signalling (and metabolomic) activation patterns and are surrounded by different stromal cells [14]. The behaviour as either rapid tumour growth or metastasis formation depends on the intercellular signalling network of the cancer cell community. In the rapidly proliferating state of individual cancer cells, stable intercellular interactions are less likely to develop. Thus, ongoing rapid proliferation can be described as growth which is more or less independent of cellular context. On the contrary, the development of the state of metastasis requires a stabilising niche even during cell migration; thus the metastatic switch is promoted by the development of a robust and resilient network of intercellular signalling cooperation [13,16–19].

Metastasis is the cause of nine out of ten deaths in cancer patients. The system-level analyses of intra- and intercellular signalling networks indicate that rapid growth and metastasis formation are often different outcomes of complex integrated molecular events.

3. Evidence from human studies

The theory that patients with a rapidly growing cancer have a poor prognostic outlook may have remained so persistent not only because it makes intuitive sense but also because empirical evidence to refute the theory is so hard to generate. Indeed, in an individual patient, the growth rate of the primary tumour is usually impossible to measure, whereas indirect estimates—such as time between onset of symptoms and diagnosis—are notoriously difficult to retrieve and interpret.

The only valid scenario that allows the identification of groups of cancers with different growth rates is in cancer screening. Patients who surface clinically with interval cancers between two screening examinations, or shortly after a negative screening (so-called interval cancers), make up one group. Interval cancers have, by definition, a detectable preclinical phase (sojourn time) which is shorter than the interval between two screening examinations [20]. The preclinical phase, as a measure of growth rate, would be shorter the sooner the cancer is detected after a negative screening. The valid comparison group comprises patients unaffected by screening, diagnosed in routine clinical practice due to symptomatic disease; because of length-bias sampling and over-diagnosis bias—and thus over-representation of slowly growing tumours—screen-detected cancer patients do not make up a valid comparison group [20].
Hence, valid assessment of the theory that rapidly growing tumours are more lethal than slowly growing ones can be undertaken only within populations where interval cancers can be compared with cancers detected without prior or ongoing screening. To prevent confounding, a valid study also requires that interval cancers are treated according to the same principles as non-interval cancers. All these methodological challenges limit the number of informative studies substantially. Below, we provide an overview of evidence from high-quality studies for different cancer types.

4. Cervical cancer

We are aware of only one informative study based on an audit of the National Swedish Screening Program [21]. To eliminate lead-time and length-bias sampling, the investigators analysed symptomatic cervical cancers diagnosed following a negative smear. These case patients were divided into those who progressed rapidly and were detected before the next scheduled screening (interval cancer), and those who were overdue and detected after the recommended screening interval.

As shown in Fig. 1, those who surfaced clinically during the screening interval had a higher (rather than lower as the prevailing theory predicts) disease-specific survival than women diagnosed after the recommended screening interval. The difference in cure proportion was 14% [21]. The investigators also compared cancers detected at screening within the recommended interval with those detected later, but found no appreciable difference in the overall excellent prognostic outlook (Fig. 1). Thus, this large population-based study provided no evidence that rapidly growing cervical cancers have a poor prognosis.

5. Breast cancer

A few small studies with suboptimal design have analysed prognosis of interval cancer (cf. Ref. [22]). An early study with an ideal (randomised) design but low statistical power provided no support for the theory of a worse prognostic outlook among interval cancers [23]. A more recent and much larger observational study took advantage of the stepwise introduction of the nationwide mammography screening program in Norway [22]. Authors compared prognosis among 1816 women with interval cancers and 5300 diagnosed before they had been invited to mammography screening. After 10 years of follow-up, survival was virtually identical in women with interval cancer (79.1%) and women in the non-screened group (76.8%; \( P = 0.53 \); Fig. 2).

6. Colorectal cancer

We found no data in the published literature that could elucidate whether patients with rapidly growing colorectal cancers (CRCs) had a different prognostic outlook from those with slowly growing cancers. We therefore used existing, population-based databases in Sweden to identify individuals with a negative colonoscopy. We included colonoscopies performed between 1997 and 2013. We excluded individuals with earlier CRC and those with CRC diagnosed within 6 months from colonoscopy, assuming that they were overlooked at the colonoscopy (false negative) or underwent a lengthy diagnostic work-up.

During follow-up through 2013, we identified 1957 eligible individuals with a CRC diagnosed more than 6 months after the first negative colonoscopy; of these, 426 died from CRC. We fitted a multivariate Cox regression model with time since colonoscopy to CRC detection as a continuous determinant of CRC death, adjusting for age, sex, calendar time, interaction terms between the covariates and quadratic terms for age and continuous interaction terms. The hazard ratio for time
from negative colonoscopy to cancer detection was 1.00 (95% confidence interval 0.999–1.002, \( P = 0.65 \)). In another Cox regression, where time since negative examination was categorised in yearly intervals, and outcome was set to CRC death within 5 years (restricted to colonoscopies performed in 1997–2008 to allow for at least 5 years of follow-up), HR was 0.95 (\( P = 0.68 \)). Hence, our analyses do not support the theory that growth rate and prognosis are related phenomena.

7. Other cancers

The clinical landscape of prostate cancer has changed more dramatically than that of any other malignancy following the introduction of screening. Yet a valid comparison of the prognosis among men with interval cancers and those unaffected by screening is difficult because opportunistic PSA testing with over-diagnosis of non-lethal cancer has profoundly influenced the recorded incidence at the population level [24]. Even in randomised trials, contamination due to PSA testing among those assigned to no screening would bias prognostic analyses. For other cancer sites, data are sparse and confounded by opportunistic screening and over-diagnosis, and available screening modalities have a performance too poor to allow informative analyses.

8. Conclusion

The theory that rapidly growing cancers are more lethal than those that grow slowly cannot be definitely dismissed, because the null hypothesis can never be proven scientifically, only refuted. With this caveat, our summary of the human evidence shows a lack of support for the prevailing idea that rapidly growing cancers are more prone to metastasize. These data are consistent with evidence almost 70 years old from tumour biology, as well as with recent system-level analyses of intra- and intercellular signalling networks.

Our findings might have at least two practical consequences. First, the concern that length-bias sampling influences survival analyses when screened- and non-screened-detected cancers are compared [3,4] may be unfounded, although bias can arise due to lead-time and over-diagnosis of non-lethal cancer. Second, empirical support for treating interval cancers more aggressively than non-interval cancers is currently lacking.

Conflict of interest statement

None declared.

Acknowledgement

The authors thank Professor Georg Klein at the Karolinska Institutet for valuable advice. The Karolinska Institutet Distinguished Professor Award was given to Professor Hans-Olov Adami (Dnr: 2368/10-221). Research in the lab of Peter Csermely and Daniel V. Veres was supported by the Hungarian National Research, Development and Innovation Office (K115378). Louise Emilsson was funded by the Norwegian research council and Foundation Blanceflor.

References


